# Intalight

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/intalight

- Industry: Medical Devices & Equipment
- Headquarters: Luoyang, China
- Website: www.intalight.com/
- Total disclosed funding: $76M
- Latest round: Series D (Oct 31, 2025)
- Investors on record: 14

## About

Founded in 2015 and headquartered in Luoyang, China, SVision Research, Inc., doing business as Intalight, focuses on redefining visual quality through modern optical technologies. The company was established by Xianzhao Peng, a graduate of Oregon State University. Its U.S. operations are led by Joseph Garibaldi, who previously served as Vice President of Global Commercial at Optovu. In 2019, its first self-developed OCT product obtained NMPA certification and entered the market. In 2022, Intalight launched the Ruyi Whole-Eye OCT, the world’s first device integrating full-eye axis biometry, anterior and posterior OCT, and OCTA imaging capabilities. In October 2025, it closed a series D+ funding round.

The company mainly engages in the research, development, production, and sales of ophthalmic imaging equipment, which adopts the SS-OCTA algorithm, third-generation sweep, and other technologies. It also developed the Ruyi whole-eye OCT technology. It integrates clinical functions, including whole-eye axis visualization biometry, anterior segment OCT, posterior segment OCT, etc. Products and technologies can be used in the treatment of fundus disease, cataracts, refractive error, glaucoma and other diseases.

The company generates revenue primarily through the sale of ophthalmic imaging devices and after-sales support services. Income is also derived from maintenance contracts, product upgrades and distribution of diagnostic systems to hospitals and medical institutions.

The company will use the series D+ funding to advance R&D of ophthalmic intelligent diagnostic equipment and expand market deployment, supporting the continued development and commercialization of its swept-source OCT technology and related imaging solutions.

## Funding rounds

- Series D, Oct 31, 2025 — CoStone Capital, Qianhai Ark Capital
- Series D, Apr 15, 2024, $14M — Haitong Capital
- Series C, Mar 9, 2023, $43M — Addor Capital, Aier Ophthalmology, CD Capital, Langsheng Investment, Flyfot Ventures, Ming Capital, Shenzhen Capital Real Estate Fund, Qianhai Ark Capital, China Life Capital, CICC Huirong Capital, Shaanxi Shaantou Yuhua Investment Management, Lingang Lanwan Fund
- Series B, Jan 19, 2021, $15M — Langsheng Investment, Flyfot Ventures, Shaanxi Shaantou Yuhua Investment Management
- Series A, Jun 29, 2018, $3.8M — Langsheng Investment, Flyfot Ventures

## Investors

- Langsheng Investment (https://capitalatlas.ai/funds/langsheng-investment) — Series A, Series B, Series C
- Flyfot Ventures (https://capitalatlas.ai/funds/flyfot-ventures) — Series A, Series B, Series C
- Shaanxi Shaantou Yuhua Investment Management — Series B, Series C
- Addor Capital (https://capitalatlas.ai/funds/addor-capital) — Series C
- Aier Ophthalmology — Series C
- CD Capital — Series C
- Ming Capital — Series C
- Shenzhen Capital Real Estate Fund (https://capitalatlas.ai/funds/shenzhen-capital-real-estate-fund) — Series C
- Qianhai Ark Capital (https://capitalatlas.ai/funds/qianhai-ark-capital) — Series C, Series D
- China Life Capital — Series C
- CICC Huirong Capital (https://capitalatlas.ai/funds/cicc-huirong-capital) — Series C
- Lingang Lanwan Fund — Series C
- Haitong Capital (https://capitalatlas.ai/funds/haitong-capital) — Series D
- CoStone Capital (https://capitalatlas.ai/funds/costone-capital) — Series D